Key Revisions to the Chinese Guidelines for Patent Examination Supplementary Data Historically, in China, the rules on submitting supplementary data in favour of sufficiency and/or inventive step have been very strict throughout patent prosecution. This was bad news...
Overview of decision On 6 November 2020, the EPO Technical Board of Appeal (TBA) formally (and finally) handed down its written decision in T844/18 relating to priority and confirmed revocation of the Broad Institute Inc.’s CRISPR/Cas9 patent EP2771468[3]. This...
Snyders’ Heart Valve Patent Snyders’ patent was to an artificial heart valve that crucially can be inserted into place without removing the native damaged valve. This is explicitly stated in the description with further details of how the artificial valve...
Background Regeneron owned two patents relating to transgenic mice that produce hybrid antibodies containing human variable regions and mouse constant regions. More specifically, the claimed mice contain an in situ replacement at a murine chromosomal immunoglobulin...
Background In T 1063/18 (Peppers), the Board held that Rule 28(2) EPC should be disregarded, and that plants produced by essentially biological processes should be considered patentable. Specifically, the Board found that the EPO Administrative Council’s...
Recent Comments